Evaluation of information for generic drugs based on importance and necessity

Yakugaku Zasshi

Volumn 125, Issue 9, 2005, Pages 739-747

  Iijima, Hisashi ^a,b   Kamei, Miwako ^a   Koshimizu, Toshimasa ^c   Shiragami, Makoto ^a  

^a NIHON UNIVERSITY   (Japan)

^b Chiba Pharmaceutical Association   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Drug information; Generic drug; Importance factor; Necessity factor

Indexed keywords

ALFACALCIDOL; ALLOPURINOL; AMBROXOL; ATENOLOL; CILOSTAZOL; CIMETIDINE; ENALAPRIL MALEATE; GENERIC DRUG; LOXOPROFEN; LYSOZYME CHLORIDE; OXATOMIDE; PRAVASTATIN; PROBUCOL; TRIMEBUTINE MALEATE; UBIDECARENONE;

ARTICLE; DATA ANALYSIS; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; HEALTH SURVEY; JAPAN; MEDICAL PRACTICE; QUANTITATIVE ANALYSIS;

DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG TOXICITY; DRUGS, GENERIC; HUMANS; QUESTIONNAIRES;

EID: 25144473972     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi.125.739     Document Type: Article

References (18)

1. Ministry of Health and Welfare, Informal social gathering concern ideal way of medicine of the 21st century (1993).
2. Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare, Notification No. 481, Apr. 8 (1999).
3. Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare, Notification No. 666, Apr. 8 (1999).
4. Ogata H., Chozai to Joho, 5, 213-264 (1992).
5. Ministry of Health, Labour and Welfare, Research on use selection standard of generic drugs, Mar. (2003).
6. Iijima H., Koshimizu T., Jpn. J. Drug Inf., 4, 21-26 (2002).
7. Iijima H., Kurosaki T., Kamei M., Koshimizu T., Shiragami M., Drug Inf. J., 38, 265-272 (2004).
8. Iijima H., Kurosaki T., Kamei M., Koshimizu T., Shiragami M., Yakugaku Zasshi, 123, 1039-1047 (2003).
9. Iijima H., Kamei M., Koshimizu T., Shiragami M., Jpn. J. Pharm. Health Care Sci., 30, 173-179 (2004).
10. Iijima H., Kamei M., Koshimizu T., Shiragami M., Yakugaku Zasshi, 124, 341-347 (2004).
11. Marroum P. J., Gobburu J., Clin. Pharmacokinet., 41, 161-169 (2002).
12. International Conference on Harmonization, ICH Harmonised Triparitte Guideline, General Considerations for Clinical Trials, 1997.
13. Ministry of Health and Welfare, Notification No. 380, Apr. 21 (1998).
14. Chapman T. M., Goa K. L., Am. J. Cardiovasc. Drugs, 3, 117-138 (2003).
15. Suri A., Forbes W. P., Bramer S. L., Clin. Pharmacokinet., 37 (Suppl 2) 61-68 (1999).
16. Suri A., Bramer S. L., Clin. Pharmacokinet., 37 (Suppl 2) 53-59 (1999).
17. Ray A. S., Olson L., Fridland A., Antimicrob. Agents Chemother., 48, 1089-1095 (2004).
18. Nakamura T., Fukuoka M., Kayano Y., Goto N., Wakiya Y., Masada M., Jpn. J. Pharm. Health Care Sci., 31, 158-163 (2005).